Vaxcyte (PCVX) Net Equity Issued and Repurchased (2020 - 2025)

Vaxcyte (PCVX) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $264.2 million in Q1 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $264.2 million in Q1 2025; TTM through Dec 2025 was $264.2 million, a 34.84% increase from a year earlier, with the FY2025 full-year figure at $264.2 million, up 34.84% from the prior year.
• Net Equity Issued and Repurchased for Q1 2025 stood at $264.2 million, up from -$26000.0 in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for PCVX reached as high as $264.2 million in Q1 2025 and fell as low as -$46000.0 in Q4 2023.
• Historically, Net Equity Issued and Repurchased has averaged $50.9 million across 5 years, with a median of $41.8 million in 2023.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 1241.48% in 2023 and fell as far as 102.23% in 2023.
• Year by year, Net Equity Issued and Repurchased stood at $6.8 million in 2021, then slumped by 69.64% to $2.1 million in 2022, then plunged by 102.23% to -$46000.0 in 2023, then surged by 43.48% to -$26000.0 in 2024, then soared by 1016253.85% to $264.2 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $264.2 million in Q1 2025, -$26000.0 in Q4 2024, and $89.5 million in Q3 2024.